Additional Evidence of Abraxane™ Activity in Advanced Non-small Cell Lung Cancer
According to the results of a phase II clinical trial presented at the 2006 ASCO annual meeting, Abraxane™ (albumin-bound paclitaxel) in combination with Paraplatin® (carboplatin) reduced detectable cancer in 29% of previously untreated patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC).
Lung cancer remains the leading cause of cancer death in the U.S. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 75%–80% of all lung cancers. Patients with advanced NSCLC are treated with chemotherapy to alleviate the symptoms of their disease and prolong their duration of survival.
Paclitaxel is a chemotherapy drug commonly used in the treatment of several types of cancer, including NSCLC. Abraxane is a newer form of paclitaxel that is bound with albumin, a type of protein normally found in the human body. This form of paclitaxel delivers high concentrations of the active ingredient into the cancer cells with reduced incidence of side effects compared to the original form of the drug.
Abraxane is currently approved for the treatment of metastatic breast cancer that has not responded to combination chemotherapy or breast cancer that has relapsed within six months of adjuvant chemotherapy (prior therapy should have included an anthracycline unless clinically contraindicated). Abraxane is also being evaluated in the treatment of several other types of cancer.
To evaluate the combination of Abraxane and Paraplatin for the initial treatment of advanced NSCLC, researchers conducted a phase II clinical trial among 100 patients with stage IIIB or stage IV NSCLC. The patients received Abraxane at one of four different doses (225, 260, 300, or 340 mg/m2), followed by Paraplatin, every three weeks.
- 29% of patients experienced a reduction in detectable cancer.
- The most common serious adverse effects of treatment were low white blood cell count, anemia, and low platelet count.
The researchers concluded that the combination of Abraxane and Paraplatin has anticancer activity among patients with advanced NSCLC and is reasonably well tolerated.
Reference: Hawkins MJ, Georgy M, Makhson A et al. Dose Escalation Study of nab-paclitaxel Followed by Carboplatin as First Line Therapy in Advanced Non-small Cell Lung Cancer. Presented at the 2006 ASCO Annual Meeting. Abstract 7132.
Copyright © 2018 CancerConnect. All Rights Reserved.